May 7th 2024
Following treatment, 17.5% and 13% of patients reported residual depressive and anxiety symptoms.
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Presentations of Pediatric AD and Shin Guard Dermatitis
August 23rd 2022Peter Lio, MD, clinical professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine in Chicago, Illinois, discusses how atopic dermatitis presents differently in pediatric patients, and the 2021 allergen of the year, acetophenone azine associated with shin guard dermatitis.
The Cutaneous Connection: Pediatric Atopic Dermatitis and Shin Guard Dermatitis
August 16th 2022In this episode, Peter Lio, MD, and clinical professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine, discusses how atopic dermatitis presents differently in pediatric patients, and the 2021 allergen of the year, acetophenone azine associated with shin guard dermatitis.
Pharmacological Options for the Treatment of Pediatric Atopic Dermatitis
Experts treating pediatric atopic dermatitis discuss the pharmacological options for the treatment of pediatric atopic dermatitis.
Presentation and Diagnosis of Atopic Dermatitis in Pediatrics
Brittany Craiglow, MD; Raj Chovatiya, MD, PhD; and Joshua Zeichner, MD, discuss the presentation of pediatric patients with atopic dermatitis and how to properly assess and diagnose pediatric patients’ atopic dermatitis.
Psychological Impact of Atopic Dermatitis in Pediatric Patients
Elizabeth Swanson, MD, and Joshua Zeichner, MD, discuss the psychological factors impacting pediatric patients’ atopic dermatitis.
Mechanism of Action for Agents Used to Treat Pediatric Atopic Dermatitis
Joshua Zeichner, MD, and Raj Chovatiya, MD, PhD, dive deep into the pathogenesis of atopic dermatitis and discuss how agents treating atopic dermatitis work.
Characteristics of Type 2 Inflammation and the Impact of Itch
Joshua Zeichner, MD, and Vikash Oza, MD, discuss characteristics of type 2 inflammation and the impact of itching on pediatric patients with atopic dermatitis.
Pediatric Patients with Atopic Dermatitis Have an Increased Risk of Type 2 Inflammatory Diseases
July 13th 2022A better understanding of this atopic diathesis and the atopic march often seen in pediatric patients is necessary to optimally treat and manage the patient population, ideally in a multidisciplinary setting.
The Cutaneous Connection: Advancements in Atopic Dermatitis Treatment
July 12th 2022In this episode, Raj Chovatiya, MD, PhD, and assistant professor of dermatology and director of the Center for Ecezma and Itch at the Northwestern University Feinberg School of Medicine, discusses the changing field of atopic dermatitis, the importance of JAK inhibitors, and the treatment options he looks forward to.
Dupilumab Treatment Improves Sleep Quality in Moderate-to-Severe AD in Children and Their Caregivers
July 7th 2022Sleep disturbance is a significant factor in reduced quality of life for children and adolescents. A study at a poster session for the SPD 2022 47th Annual Meeting was presented on treating this population with dupilumab (Dupixent) to help with sleep quality showed positive results.